Skip to content
Screener

Relmada Therapeutics, Inc. RLMD Current Debt

Discontinued — last reported Q2 '23

Current Debt at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$11.69B+1.4%
Merck & Co. logo
Merck & Co.MRK
$2.83B+97.0%
XER
Xeris Biopharma Holdings, Inc.XERS
$63.78M—

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$526.95M+2,719%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShorttermDebtFairValue.

The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed August 8, 2023.

Filed
Aug 8, 2023
Fiscal quarter
Q2 FY2023
Calendar quarter
Q2 2023
Accession
0001213900-23-064519

Short-term investments at June 30, 2023 consisted of mutual funds with a fair value of $104,059,737.

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Relmada Therapeutics, Inc.'s current debt?
Relmada Therapeutics, Inc. (RLMD) reported current debt of $104.06M in Q2 2023.
How has Relmada Therapeutics, Inc.'s current debt changed year-over-year?
Relmada Therapeutics, Inc.'s current debt decreased by 40.4% year-over-year, from $174.69M to $104.06M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Relmada Therapeutics, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude